308 related articles for article (PubMed ID: 22964634)
1. Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer.
Kulak MV; Cyr AR; Woodfield GW; Bogachek M; Spanheimer PM; Li T; Price DH; Domann FE; Weigel RJ
Oncogene; 2013 Aug; 32(34):4043-51. PubMed ID: 22964634
[TBL] [Abstract][Full Text] [Related]
2. Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure.
Woodfield GW; Hitchler MJ; Chen Y; Domann FE; Weigel RJ
Clin Cancer Res; 2009 Jun; 15(11):3672-9. PubMed ID: 19458056
[TBL] [Abstract][Full Text] [Related]
3. Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells.
Woodfield GW; Chen Y; Bair TB; Domann FE; Weigel RJ
Genes Chromosomes Cancer; 2010 Oct; 49(10):948-62. PubMed ID: 20629094
[TBL] [Abstract][Full Text] [Related]
4. TFAP2C regulates carbonic anhydrase XII in human breast cancer.
Franke CM; Gu VW; Grimm BG; Cassady VC; White JR; Weigel RJ; Kulak MV
Oncogene; 2020 Feb; 39(6):1290-1301. PubMed ID: 31636386
[TBL] [Abstract][Full Text] [Related]
5. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
Mossman D; Kim KT; Scott RJ
BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
[TBL] [Abstract][Full Text] [Related]
6. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.
Xu J; Huo D; Chen Y; Nwachukwu C; Collins C; Rowell J; Slamon DJ; Olopade OI
Breast Cancer Res Treat; 2010 Apr; 120(3):593-601. PubMed ID: 19466541
[TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
8. Expression of the RET proto-oncogene is regulated by TFAP2C in breast cancer independent of the estrogen receptor.
Spanheimer PM; Woodfield GW; Cyr AR; Kulak MV; White-Baer LS; Bair TB; Weigel RJ
Ann Surg Oncol; 2013 Jul; 20(7):2204-12. PubMed ID: 22878616
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of glutathione peroxidase 1 (GPX1) down-regulation and correlation with aberrant promoter methylation in human gastric cancer.
Min SY; Kim HS; Jung EJ; Jung EJ; Jee CD; Kim WH
Anticancer Res; 2012 Aug; 32(8):3169-75. PubMed ID: 22843889
[TBL] [Abstract][Full Text] [Related]
10. TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling.
Woodfield GW; Horan AD; Chen Y; Weigel RJ
Cancer Res; 2007 Sep; 67(18):8439-43. PubMed ID: 17875680
[TBL] [Abstract][Full Text] [Related]
11. DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma.
Peng DF; Razvi M; Chen H; Washington K; Roessner A; Schneider-Stock R; El-Rifai W
Gut; 2009 Jan; 58(1):5-15. PubMed ID: 18664505
[TBL] [Abstract][Full Text] [Related]
12. EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.
De Andrade JP; Park JM; Gu VW; Woodfield GW; Kulak MV; Lorenzen AW; Wu VT; Van Dorin SE; Spanheimer PM; Weigel RJ
Mol Cancer Ther; 2016 Mar; 15(3):503-11. PubMed ID: 26832794
[TBL] [Abstract][Full Text] [Related]
13. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
[TBL] [Abstract][Full Text] [Related]
14. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine.
David GL; Yegnasubramanian S; Kumar A; Marchi VL; De Marzo AM; Lin X; Nelson WG
Cancer Biol Ther; 2004 Jun; 3(6):540-8. PubMed ID: 15034303
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q
Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional regulation of mouse delta-opioid receptor gene by CpG methylation: involvement of Sp3 and a methyl-CpG-binding protein, MBD2, in transcriptional repression of mouse delta-opioid receptor gene in Neuro2A cells.
Wang G; Wei LN; Loh HH
J Biol Chem; 2003 Oct; 278(42):40550-6. PubMed ID: 12890683
[TBL] [Abstract][Full Text] [Related]
17. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation.
Wu Y; Alvarez M; Slamon DJ; Koeffler P; Vadgama JV
BMC Cancer; 2010 Feb; 10():32. PubMed ID: 20132554
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas.
You Y; Yang W; Wang Z; Zhu H; Li H; Lin C; Ran Y
Cell Oncol (Dordr); 2013 Jul; 36(4):323-31. PubMed ID: 23740091
[TBL] [Abstract][Full Text] [Related]
19. Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.
Zhang YW; Staal B; Dykema KJ; Furge KA; Vande Woude GF
PLoS One; 2012; 7(6):e38955. PubMed ID: 22701735
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation-dependent silencing of CST6 in human breast cancer cell lines.
Rivenbark AG; Jones WD; Coleman WB
Lab Invest; 2006 Dec; 86(12):1233-42. PubMed ID: 17043665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
